Nyxoah appoints Liam Kelly as Chief Executive Officer

Nyxoah SA, a medical technology company specializing in neuromodulation treatments for Obstructive Sleep Apnea (OSA), has appointed Liam Kelly as its new Chief Executive Officer. Effective October 1, 2026, Kelly succeeds Olivier Taelman.

The appointment is intended to strengthen Nyxoah’s commercial focus on the United States following the FDA approval and launch of its Genio device. Kelly brings over 25 years of leadership experience to the role, having previously served as Chairman, President, and CEO of Teleflex Incorporated. He also held senior management positions at Hill-Rom Holdings, Inc. and currently serves as a director of Enovis Corporation.